Regeneron Pharmaceuticals stock

REGN · NASDAQ · USD

$955.47Change from previous close: +0.45%Absolute change: +$4.28

Close · November 13, 2026

Price history

+37.48% over the period

1 year: from $694.99 (November 13, 2025) to $955.47 (November 13, 2026), +37.48%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$955.47
October 30, 2026$927.89
September 30, 2026$758.27
August 31, 2026$799.08
July 31, 2026$762.63
June 30, 2026$623.54
May 29, 2026$614.78
April 30, 2026$707.06
March 31, 2026$772.64
February 27, 2026$781.67
January 30, 2026$741.45
December 31, 2025$771.87
November 28, 2025$780.19
November 13, 2025$694.99

At a glance

TickerLandia's take on Regeneron Pharmaceuticals

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$591.52
52-wk high$991.73

−3.66% from the 52-week high

Analysts · 28 analysts

Average target$984.96+3.09% vs. price

Buy 19 · Hold 9 · Sell 0 · Buy

TickerLandia Fingerprint: Regeneron Pharmaceuticals

Compared with similar companies: very strong momentum.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Regeneron Pharmaceuticals is pricier than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Regeneron Pharmaceuticals's P/E today is 23.0, above the median of its last 10 fiscal years (18.7; between 8.77 and 47.7 from 2016 to 2025). Regeneron Pharmaceuticals's P/E (trailing 12 months): 21.1, −39% against the median of a group of 7 similar companies (34.7).

P/E compared with its history

Compared with 7 similar companies

Regeneron Pharmaceuticals's metrics compared with similar companies
MetricRegeneron PharmaceuticalsPosition in the groupBand
P/E (trailing 12 months)21.1Low
Forward P/E13.5Low
Operating margin30.4%Middle
ROE14.9%Middle
Debt/equity0.08Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Regeneron Pharmaceuticals. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$5.12B

Latest quarter · Q3 2026

Net income

$1.95B

Latest quarter · Q3 2026

Quarterly net margin

38.1%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$98.84B
P/E
21.1
EPS
$45.24
Volume
1.17M
Daily trading
€823.99M
Dividend yield
0.39%

How Regeneron Pharmaceuticals is changing

All results
  • Revenue grew 11.0% a year on average over the last 5 years

  • Operating margin fell from 38.9% to 24.9%

  • Profits turn into cash: free cash flow equal to 90% of net income

Returns

Regeneron Pharmaceuticals returns with dividends

$1,000 invested in Regeneron Pharmaceuticals 5 years ago, on November 15, 2021, would be worth $1,475 today: +47.51% in total, +8.10% per year. This is the price return only: dividends are excluded.

PeriodRegeneron PharmaceuticalsS&P 500$1,000 becomes
1 month+26.87%−3.12%$1,269
6 months+32.73%+1.58%$1,327
Year to date+23.79%+10.46%$1,238
1 year+38.17%+12.23%$1,382
3 years+19.93%+71.41%$1,199
5 years+47.51%+61.48%$1,475
10 years+114.94%+249.40%$2,149

Over the last 6 months it has done better than 70% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

Regeneron Pharmaceuticals: technical analysis

Regeneron Pharmaceuticals is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 20.5% below its all-time closing high ($1,201.76, August 27, 2024).

Trend
Upward
RSI (14 sessions)
68
Between 30 and 70
vs 200-session average
+27.92%

Support and resistance

Price areas where Regeneron Pharmaceuticals has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$955.47
  3. Support$853.17−10.71%2 touches, last on September 3, 2026
  4. Support$816.55−14.54%3 touches, last on September 23, 2026
  5. Support$792.84−17.02%3 touches, last on March 3, 2026

Volatility and risk

Over the last year it has moved little with the S&P 500.

Beta (1 year) vs S&P 500
0.38
Volatility (60 sessions, annualised)
39.5%
Largest fall in the last year
−26.05%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Regeneron Pharmaceuticals: seasonality

Average monthly price change over 36 years

+3.7%Jan+8.7%Feb−4.3%Mar+1.4%Apr+5.3%May+0.7%Jun+5.7%Jul+2.4%Aug+2.1%Sep+0.5%Oct+4.6%Nov+4.3%Dec

Over the last 36 years, the strongest month for Regeneron Pharmaceuticals has been February: +8.66% on average, positive in 15 years out of 35. The weakest has been March: −4.33% on average, positive in 16 years out of 35. November, the current month, has been positive in 19 years out of 35 (+4.61% on average).

Show chart data
MonthAverageMedianPositive years
January+3.71%+1.02%18 of 35
February+8.66%−2.08%15 of 35
March−4.33%−0.37%16 of 35
April+1.38%−1.13%16 of 35
May+5.27%+2.18%22 of 36
June+0.71%−0.70%16 of 36
July+5.72%+3.63%24 of 36
August+2.35%+4.43%20 of 36
September+2.12%−0.93%16 of 36
October+0.50%−3.80%15 of 36
November+4.61%+0.66%19 of 35
December+4.34%−0.30%16 of 35

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Regeneron Pharmaceuticals and its competitors

Its product line begins with EYLEA injections, used for wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinopathy of prematurity. The company also offers Dupixent for atopic dermatitis and asthma, Libtayo for metastatic or locally advanced cutaneous squamous cell carcinoma, Praluent for heterozygous familial hypercholesterolemia and Kevzara for rheumatoid arthritis.

Headquarters
Tarrytown, United States
Employees
15,410
Founded
1988
Chief executive
Leonard Schleifer
Regeneron Pharmaceuticals and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Regeneron PharmaceuticalsREGN$98.84B30.4%21.1+32.73%
ModernaMRNA$90.38B-80.8%—+343.02%
Vertex PharmaceuticalsVRTX$136.56B37.8%34.7+18.88%
argenxARGX$60.37B31.9%33.3+19.60%
BeOne MedicinesONC$47.58B17.8%53.4+31.59%
Royalty PharmaRPRX$39.85B64.4%45.3+30.16%

Same industry or related industries, similar size. Compare Regeneron Pharmaceuticals with its competitors · Full profile